Shares of medical device major DexCom (NASDAQ:DXCM) are ticking higher today after its Stelo Glucose monitor became the first biosensor device to be cleared for over-the-counter (OTC) use by the U.S. Food and Drug Administration (FDA). Stelo utilizes a wearable sensor. The device can provide insights directly to smart devices such as a user’s phone. The monitor is expected to be available online starting this summer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to DexCom, nearly 25 million people in the U.S. who are living with type 2 diabetes but do not use insulin can benefit from the technology. DXCM’s DexCom 7 glucose monitoring device is already available in the market with a prescription. Now, Stelo is expected to further boost access to continuous glucose monitoring solutions.
Is DXCM a Good Stock to Buy?
DexCom’s share price has rallied by nearly 14% over the past six months. Overall, the Street has a Strong Buy consensus rating on DexCom. Further, an average price target of $149 implies a 22.35% potential upside in DXCM stock. However, a price-to-earnings multiple of 92.9 means shares of the company aren’t exactly cheap at current price levels.
Read full Disclosure